Analyst Ratings for Acadia Pharmaceuticals (ACAD)
ACAD Rating Summary
ACAD Price Target Summary
- Highest: $40.00 (UBS)
- Lowest: $15.00 (Goldman Sachs)
- Average: $30.41
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$30.41 (+40%)
* Over Last 12-Mos
Rating Score: 5.9 / 10
Percentile Rank: 62%
Avg. $ Target:
$30.41 (+40%)
* Over Last 12-Mos
Rating Score: 5.9 / 10
Percentile Rank: 62%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 3/25/2026 | BofA Securities | Tazeen Ahmad | Upgrade | Buy (Neutral) |
29.00 (N/A) |
20.96 (21.72) |
3.63% | Details |
| 2/24/2026 | Wolfe Research | Rudy Li | New Coverage | Outperform (N/A) |
33.00 (N/A) |
23.99 (21.72) |
-9.46% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
